Ibogamine congeners

US6211360A · kind A · utility

Assignees

• Albany Medical College · US
• University of Vermont · US

Inventors

• Stanley D. Glick · Delmar, US
• Martin E. Kuehne · Burlington, US

Key dates

• Filing date: Aug 31, 1998
• Grant date: Apr 3, 2001
• Expiry date: Aug 31, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to compounds having formula (1), wherein n is from 0 to 8; R.sup.1 is CH.sub.2 OH, CH(OH)R.sup.5, CH.sub.2 OR.sup.5, CO.sub.2 R.sup.5, C(O)NH.sub.2, C(I)NHR.sup.5, C(O)NR.sup.5 R.sup.6, C(O)NHNH.sub.2, C(O)NHNHR.sup.5, C(O)NHNR.sup.5 R.sup.6, C(O)NR.sup.5 NH.sub.2, C(O)NR.sup.5 NHR.sup.6, C(O)NR.sup.5 NR.sup.6 R.sup.7, C(O)NHNH(C(O)R.sup.5), C(O)NHNR.sup.5 (C(O)R.sup.6) C(O)NR.sup.5 NH(C(O)R.sup.6), C(O)NR.sup.5 NR.sup.6 (C(O)R.sup.7), CN, or C(O)R.sup.5 ; R.sup.2 is H, unsubstituted or substituted alkyl, YH, YR.sup.8, YC(O)R.sup.8, C(O)YR.sup.8, C(O)NH.sub.2, C(O)NHR.sub.8, C(O)NR.sup.8 R.sup.9, NH.sub.2, NHR.sup.8, NR.sup.8 R.sup.9, NHC(O)R.sup.8, or NR.sup.8 C(O)R.sup.9 ; R.sup.3 and R.sup.4 are the same or different and are selected from the group consisting of H, halogens, unsubstituted or substituted alkyl, OH, OR.sup.10, NH.sub.2, NHR.sup.10, NR.sup.10 R.sup.11, NHC(O)R.sup.10, or NR.sup.10 C(O)R.sup.11 ; R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, and R.sup.11 are the same or different and are selected from the group consisting of unsubstituted alkyl and substituted alkyl and substituted alkyl; R.sup.12 is selected from the group…